Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation (STAT)

This study has been completed.
Sponsor:
Collaborators:
Sanofi
University of Arizona
Wake Forest University
University of Nebraska
The Methodist Hospital System
Information provided by (Responsible Party):
R. Brian Stevens, MD, PhD, FACS, FAST, Wright State University
ClinicalTrials.gov Identifier:
NCT00906204
First received: May 19, 2009
Last updated: November 2, 2015
Last verified: November 2015

May 19, 2009
November 2, 2015
March 2010
July 2014   (final data collection date for primary outcome measure)
Composite Endpoint of 5 Components: Fever, Hypoxia, Hypotension, Cardiac Events, and Delayed Graft Function [ Time Frame: During first 7 days after kidney transplantation ] [ Designated as safety issue: Yes ]

The composite endpoint components and definitions are:

  • Fever: Body temperature ≥ 38.5˚C.
  • Hypotension: After rATG initiation, systolic blood pressure ≤ 90 mmHg requiring de novo treatment with vasopressors.
  • Hypoxia: During transplantation surgery, increase in FiO2 to ≥ 60% following rATG initiation. Following transplantation, starting in recovery room, FiO2 ≥ 50% or nasal cannula delivering ≥ 3 liters, either singly or combined, for > 12 hours out of a 24 hour period.
  • Cardiac events: Myocardial Infarction, clinically significant dysrhythmia (atrial fibrillation, atrial flutter, ventricular fibrillation and ventricular tachycardia)
  • Delayed graft function (DGF): Requirement for dialysis within 7 days of transplantation
Composite Endpoint of 5 Components: Fever, Hypoxia, Hypotension, Cardiac Events, and Delayed Graft Function [ Time Frame: During first 7 days after kidney transplantation ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00906204 on ClinicalTrials.gov Archive Site
  • Patient Survival [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
    Kaplan-Meier estimate of the number of patients who survived for the 12 months after kidney transplantation.
  • Graft Survival [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
    Kaplan-Meier estimates of graft survival probability for 12 months after transplantation
  • Acute Kidney Rejection [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
    Kaplan-Meier probability estimates of rejection rates
  • Incomplete Thymoglobulin Infusion [ Time Frame: First 7 days post-transplantation ] [ Designated as safety issue: Yes ]
  • Kidney Function [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: No ]
    Estimated Glomerular Filtration Rate using the abbreviated MDRD formula (Modification of Diet in Renal Disease study)
  • Patient Survival [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
  • Graft Survival [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
  • Acute rejection of transplanted kidney; biopsy-confirmed, clinically symptomatic [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
  • Incomplete Thymoglobulin Infusion [ Time Frame: First 7 days post-transplantation ] [ Designated as safety issue: Yes ]
  • Short-term kidney function (Immediately after transplantation) [ Time Frame: Post-transplantation days 1-4 ] [ Designated as safety issue: No ]
  • Longer-term kidney function [ Time Frame: Post-transplantation months 3 - 12 ] [ Designated as safety issue: No ]
  • Hematologic effects of Thymoglobulin administration (Effects of the 2 different dosing plans on white and red blood cells and platelets) [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: Yes ]
  • Immunologic effects of Thymoglobulin administration (studies of antibodies and specific immune cell types in the blood after transplantation) [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: No ]
  • Histopathology of kidney biopsies taken at transplantation and after 12 months [ Time Frame: 12 months post-transplantation ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Trial to Assess Safety of Single Dose vs. Traditional Administration of Thymoglobulin Induction for Renal Transplantation
In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better kidney function than the standard dosing plan, when the same amount is divided into smaller doses on 4 days. This new study repeats that dose comparison, but with double-blinding and at multiple transplantation centers.

This study is designed to confirm the one-year safety of single-dose rabbit anti-thymocyte globulin induction at kidney transplantation, compared to the conventional administration of the same overall dose divided into four smaller doses across four days. Two randomized groups of kidney transplant recipients will be each administered the drug Thymoglobulin according to a different dosing regimen. The control group will receive the usual and traditional regimen of a total of 6 mg/Kg divided into 4 doses, 1 on the day of transplantation and 1 each day on the next 3 days. The experimental group will receive the same total Thymoglobulin dose, 6 mg/Kg, but entirely on the day of transplantation.

The study will be double-blinded, with placebo doses of Thymoglobulin administered as needed to enrollees in the experimental group. Enrollment is targeted at 165, with 150 subjects needed to complete the study for adequate evaluation.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • End-Stage Renal Disease
  • Kidney Failure
  • Biological: Single-dose rabbit Anti-thymocyte Globulin induction
    6 mg of rATG administered in a single dose on the day of kidney transplantation
    Other Names:
    • Thymoglobulin
    • rATG
  • Biological: Divided-dose rabbit Anti-thymocyte Globulin induction
    6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
    Other Names:
    • Thymoglobulin
    • rATG
  • Experimental: Single-dose Thymoglobulin
    Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
    Intervention: Biological: Single-dose rabbit Anti-thymocyte Globulin induction
  • Active Comparator: Divided-dose Thymoglobulin
    Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
    Intervention: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation
  • Male or female subject who has reached legal age in the state where they reside and is at least 18 years of age
  • Deceased or living donors
  • Compatible ABO blood type
  • Expanded-criteria donor (ECD) kidneys with a donor grade score of ≤ 25 (as developed by Nyberg, et al.)
  • If Kidneys are pumped, they must meet the following pumping parameters: resistance <0.35 with a flow rate of >60 ml/min.

Exclusion Criteria:

  • Recipient age >65 years
  • PRA >50%, or donor-specific antibody
  • CIT >30 hours
  • Re-transplant patients
  • Multi-organ transplant recipients (example: kidney/pancreas or kidney/liver)
  • Renal transplant recipients planned for future pancreas transplantation
  • Current unstable cardiovascular disease or history of myocardial infarction within the previous 6 months
  • Current malignancy or history or malignancy (within the previous 5 years) with the exception of non-metastatic basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully.
  • Hepatitis B and C recipients or active liver disease
  • HIV positive recipients
  • Primary disease requiring treatment with steroids after transplantation
  • Expanded-criteria donor kidneys (current UNOS criteria) with a donor grade score of > 25
  • Donation after cardiac death (DCD) donors
  • Dual adult kidneys
  • Recipients of pediatric (age <12 years) unilateral or en-bloc kidneys
  • Previous treatment with rATG
  • Known hypersensitivity, extensive exposure, or allergy to rabbits
  • Pregnant
  • Any condition that in the investigator's opinion may compromise study participation (e.g., history or likelihood of non-compliance with immunosuppression regimen, protocol visits, tests, and studies)

Relative Exclusion Criteria:

  • Patients with a BMI > 37 should be considered on an individual basis based on overall health and body habitus.
Both
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00906204
183-09-FB
Yes
Not Provided
Not Provided
R. Brian Stevens, MD, PhD, FACS, FAST, Wright State University
Wright State University
  • Sanofi
  • University of Arizona
  • Wake Forest University
  • University of Nebraska
  • The Methodist Hospital System
Principal Investigator: R.Brian Stevens, MD, PhD Wright State University, Dayton, Ohio
Wright State University
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP